Hepatocellular Carcinoma

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Hepatocellular carcinoma is the third most frequent cause of death from cancer worldwide. This cancer is most common in geographic regions with a high prevalence of chronic hepatitis B virus infection-particularly in Asia and sub-Saharan Africa. However, due to increased incidence of chronic hepatitis C virus infection between 1945 and 1990, the incidence rates of hepatocellular carcinoma have been increasing in Europe and North America since the 1970s. Substantial advances have been made in therapy of hepatocellular carcinoma, notably the recognition that in patients with early stage disease liver transplantation can achieve a 5-year survival of over 70%. These results, along with advances in surgical resection, local ablation, and locoregional therapies, have led to an increased emphasis on surveillance of individuals at risk for hepatocellular carcinoma, to allow for early diagnosis and more effective treatment of as many patients as possible. For patients with advanced, unresectable disease, the recent FDA approval of the multikinase inhibitor sorafenib, which has been shown to moderately extend patient survival, is a positive harbinger for future advances in therapy.

Original languageEnglish (US)
Title of host publicationPractical Gastroenterology and Hepatology: Liver and Biliary Disease
PublisherWiley-Blackwell
Pages144-151
Number of pages8
ISBN (Print)9781405182751
DOIs
StatePublished - Aug 31 2010

Fingerprint

Hepatocellular Carcinoma
Virus Diseases
Survival
Africa South of the Sahara
Incidence
Chronic Hepatitis B
Chronic Hepatitis C
Therapeutics
North America
Hepatitis B virus
Hepacivirus
Liver Transplantation
Early Diagnosis
Cause of Death
Neoplasms

Keywords

  • Chemoembolization
  • Cirrhosis
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular carcinoma
  • Liver transplantation
  • Percutaneous ethanol injection
  • Radioembolization
  • Radiofrequency ablation
  • Sorafenib

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roberts, L. R. (2010). Hepatocellular Carcinoma. In Practical Gastroenterology and Hepatology: Liver and Biliary Disease (pp. 144-151). Wiley-Blackwell. https://doi.org/10.1002/9781444325249.ch15

Hepatocellular Carcinoma. / Roberts, Lewis Rowland.

Practical Gastroenterology and Hepatology: Liver and Biliary Disease. Wiley-Blackwell, 2010. p. 144-151.

Research output: Chapter in Book/Report/Conference proceedingChapter

Roberts, LR 2010, Hepatocellular Carcinoma. in Practical Gastroenterology and Hepatology: Liver and Biliary Disease. Wiley-Blackwell, pp. 144-151. https://doi.org/10.1002/9781444325249.ch15
Roberts LR. Hepatocellular Carcinoma. In Practical Gastroenterology and Hepatology: Liver and Biliary Disease. Wiley-Blackwell. 2010. p. 144-151 https://doi.org/10.1002/9781444325249.ch15
Roberts, Lewis Rowland. / Hepatocellular Carcinoma. Practical Gastroenterology and Hepatology: Liver and Biliary Disease. Wiley-Blackwell, 2010. pp. 144-151
@inbook{f7784c6d611344bc8cd6a83a66868487,
title = "Hepatocellular Carcinoma",
abstract = "Hepatocellular carcinoma is the third most frequent cause of death from cancer worldwide. This cancer is most common in geographic regions with a high prevalence of chronic hepatitis B virus infection-particularly in Asia and sub-Saharan Africa. However, due to increased incidence of chronic hepatitis C virus infection between 1945 and 1990, the incidence rates of hepatocellular carcinoma have been increasing in Europe and North America since the 1970s. Substantial advances have been made in therapy of hepatocellular carcinoma, notably the recognition that in patients with early stage disease liver transplantation can achieve a 5-year survival of over 70{\%}. These results, along with advances in surgical resection, local ablation, and locoregional therapies, have led to an increased emphasis on surveillance of individuals at risk for hepatocellular carcinoma, to allow for early diagnosis and more effective treatment of as many patients as possible. For patients with advanced, unresectable disease, the recent FDA approval of the multikinase inhibitor sorafenib, which has been shown to moderately extend patient survival, is a positive harbinger for future advances in therapy.",
keywords = "Chemoembolization, Cirrhosis, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Liver transplantation, Percutaneous ethanol injection, Radioembolization, Radiofrequency ablation, Sorafenib",
author = "Roberts, {Lewis Rowland}",
year = "2010",
month = "8",
day = "31",
doi = "10.1002/9781444325249.ch15",
language = "English (US)",
isbn = "9781405182751",
pages = "144--151",
booktitle = "Practical Gastroenterology and Hepatology: Liver and Biliary Disease",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Hepatocellular Carcinoma

AU - Roberts, Lewis Rowland

PY - 2010/8/31

Y1 - 2010/8/31

N2 - Hepatocellular carcinoma is the third most frequent cause of death from cancer worldwide. This cancer is most common in geographic regions with a high prevalence of chronic hepatitis B virus infection-particularly in Asia and sub-Saharan Africa. However, due to increased incidence of chronic hepatitis C virus infection between 1945 and 1990, the incidence rates of hepatocellular carcinoma have been increasing in Europe and North America since the 1970s. Substantial advances have been made in therapy of hepatocellular carcinoma, notably the recognition that in patients with early stage disease liver transplantation can achieve a 5-year survival of over 70%. These results, along with advances in surgical resection, local ablation, and locoregional therapies, have led to an increased emphasis on surveillance of individuals at risk for hepatocellular carcinoma, to allow for early diagnosis and more effective treatment of as many patients as possible. For patients with advanced, unresectable disease, the recent FDA approval of the multikinase inhibitor sorafenib, which has been shown to moderately extend patient survival, is a positive harbinger for future advances in therapy.

AB - Hepatocellular carcinoma is the third most frequent cause of death from cancer worldwide. This cancer is most common in geographic regions with a high prevalence of chronic hepatitis B virus infection-particularly in Asia and sub-Saharan Africa. However, due to increased incidence of chronic hepatitis C virus infection between 1945 and 1990, the incidence rates of hepatocellular carcinoma have been increasing in Europe and North America since the 1970s. Substantial advances have been made in therapy of hepatocellular carcinoma, notably the recognition that in patients with early stage disease liver transplantation can achieve a 5-year survival of over 70%. These results, along with advances in surgical resection, local ablation, and locoregional therapies, have led to an increased emphasis on surveillance of individuals at risk for hepatocellular carcinoma, to allow for early diagnosis and more effective treatment of as many patients as possible. For patients with advanced, unresectable disease, the recent FDA approval of the multikinase inhibitor sorafenib, which has been shown to moderately extend patient survival, is a positive harbinger for future advances in therapy.

KW - Chemoembolization

KW - Cirrhosis

KW - Hepatitis B

KW - Hepatitis C

KW - Hepatocellular carcinoma

KW - Liver transplantation

KW - Percutaneous ethanol injection

KW - Radioembolization

KW - Radiofrequency ablation

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84885976153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885976153&partnerID=8YFLogxK

U2 - 10.1002/9781444325249.ch15

DO - 10.1002/9781444325249.ch15

M3 - Chapter

AN - SCOPUS:84885976153

SN - 9781405182751

SP - 144

EP - 151

BT - Practical Gastroenterology and Hepatology: Liver and Biliary Disease

PB - Wiley-Blackwell

ER -